Drugs in Dev.
Pulmonary/Respiratory Diseases
Phase III
Finland 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product
Details : Budesonide is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
December 04, 2014
Lead Product(s) : Budesonide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Faron Secures U.S. Rights to Patent Related to Traumakine
Details : The agreement clarifies Faron's intellectual property position in the U.S. ahead of any launch of Traumakine for the treatment of capillary leak and systemic inflammatory response syndromes including acute respiratory distress syndrome (ARDS) in the U.S.
Product Name : Traumakine
Product Type : Protein
Upfront Cash : Undisclosed
May 14, 2021
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Detailed analyses following INTEREST trial conclude glucocorticoids block the upregulation of CD73 in the lung capillaries and inhibit interferon signalling.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 20, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Seventh Framework Programme (FP7)
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Interferon Beta-1a is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Respiratory Distress Syndrome.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 04, 2015
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Seventh Framework Programme (FP7)
Deal Size : Inapplicable
Deal Type : Inapplicable



